[8]Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Th...
今年7月15日,《细胞》杂志(Cell)在线发布上海长征医院等机构联合专家团队的最新研究结果,通过我国自主研发的“通用型”CAR-T疗法TyU19,成功治疗了3名患有严重复发难治性风湿免疫疾病的患者。 这3名首批患者的恢复超出预期:一名肌无力女性患者在接受治疗两周后,重新获得了抬手梳头的力量;另两名系统性硬化症男性患者...
[1]Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost. Nature. 2024 Mar;627(8005):709-710. doi:10.1038/d41586-024-00809-y. PMID: 38514877.[2]AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metas...
3月21日, 《Nature》报道了印度开发出一款用于血液癌症治疗的异体嵌合抗原受体(CAR)-T细胞疗法,即NexCAR19。早期临床试验显示,大多数人在1个月的随访中肿瘤完全消失或缩小。值得注意的是,其单次治疗费用在 3…
4. Karulkar A, Jaiswal AK, Khan A, et al. Excellent safety profile of a low-cost novel humanized CD19 CAR T-cell therapy, Actalycabtagene Autoleucel: Potential impact on access and feasibility. Blood 2023;142 (Supplement 1): 257. ...
2. India’s First Homegrown CAR T-Cell Therapy - NCI (cancer.gov) 3.Mira's Lymphoma Warrior Journey: Hope and CAR-T Therapy - Mindful Cells 4.Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy | Blood | American Societ...
1. Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost (nature.com)2. India’s First Homegrown CAR T-Cell Therapy - NCI (cancer.gov)3.Mira's Lymphoma Warrior Journey: Hope and CAR-T Therapy - Mindful Cells 4.Phase I Trial of Humanized CD19 CART-Cell ...
-- Dr. Eric Smith, Director Translational Development, Cellular Therapeutics Center; Assistant Attending, Myeloma Service, Memorial Sloan Kettering Cancer Center [ Advances in CAR T cell therapy for Multiple Myeloma: 靶向B-细胞成熟抗原(BCMA)的多发性骨髓瘤嵌合抗原受体T细胞(CAR-T)疗法 ] ...
终于在父母的坚持不懈下得到消息,可以在一项试验中用CAR-T细胞治疗他们的第一位儿科复发/难治性急性淋巴细胞白血病(ALL)患者。 2012年4月,艾米莉成功进行了CAR-T细胞疗法的治疗。一个月后,她体内的癌细胞完全清除,之后也一直处于缓解状态。艾米莉至今已经无癌生存超十年,她体内再也找不到癌细胞了,在临床上等同于“...
近日,科济生物官网披露一则重磅消息:我国自主研发的CAR-T产品——satri-cel(CT041),其关键性II期临床试验CT041-ST-01(NCT04581473)斩获积极成果。 Satri-cel是一种针对Claudin18.2的自体CAR-T细胞候选产品,主要针对Claudin18.2阳性实体...